"[The PREVAIL Act] would update and improve our country's #patent system by implementing much-needed reforms to #PTAB and creating a fairer system for #innovators and #researchers."
- Rep. Deborah Ross (D-NC)
For more insights:
How the Patent Office Can Impact Litigation
Click the bio link to listen to the full episode.
https://bio.link/robertarnett
#JRobertArnettII #PatentLitigation #PTO #PatentValidity #PTAB #LegalStrategy #IntellectualProperty #CourtProcess
#ICYMI: Check out our fact sheet, which compares the #PREVAILAct's proposed #PTAB framework to prior and current #USPTO approaches.
It explains how the bill would end the cycle of policy shifts between administrations.
🗞️ #ICYMI: Gary Locke, C4IP board member and former U.S. ambassador to China, penned an opinion essay underscoring the need for #patent subject matter eligibility reform, #PTAB reform, and stronger injunctive relief for the #U.S. to stay ahead of #China's rapidly growing #biotech sector.
Read it 👇
📜 The #PREVAILAct would ensure that the #PTAB meets the #AmericaInventsAct's original goals: a #patent system that is efficient, predictable, and fair.
PREVAIL would also ensure an equal playing field for the many small and independent #inventors competing against large incumbents.
For more:
Congress meant for the PTAB and #IPRs (when properly configured) to have an important role to play in the #patent ecosystem.
The bipartisan, bicameral #PREVAILAct presents a clear and important opportunity to cement long-needed #PTAB changes.
For more, check out our recent letter to the #USPTO:
Why does #C4IP support the #PREVAILAct? ⬇️
By eliminating needless duplication, the PREVAIL Act promotes efficiency and fairness.
The PREVAIL Act also aligns #PTAB and district court standards, creating a more rational and equitable #patent system.
Learn more:
Edition 38 of C4IP's #IP Policy Roundup newsletter is now live!
In this edition, we fact-check claims about #PERA and #PTAB reform efforts, unpack the latest updates in the world of IP, spotlight the #inventor of drywall, Augustine Sackett, and much more.
Read it here ⬇️
The #USPTO's #NPRM would be particularly beneficial in providing the sort of long-term predictability and stability that is important to the #patent system.
But more can be done to cement long-needed #PTAB changes.
Learn more:
The #USPTO's proposed new rules seek to address longstanding imbalances in the operations of #IPRs before the #PTAB.
We detailed our examination of the proposal in a new public comment.
Read it here:
C4IP commends the #USPTO and Director Squires for taking formal steps to address longstanding imbalances in the operations of IPRs before the #PTAB.
Moreover, we believe the bipartisan, bicameral #PREVAILAct presents a clear and important opportunity to cement long-needed PTAB changes.
For more:
#ICYMI: C4IP Chief Policy Officer and Counsel Jamie Simpson spoke on a Federalist Society panel titled "SAP, Motorola, and the Future of #PTAB Reform," where she joined other #legal experts to discuss recent #Patent Trial and Appeal Board developments.
For more:
Check out our new infographic on the #PREVAIL Act!
It highlights the importance of the #bill and outlines how PREVAIL compares to the current and previous administration's #PTAB procedures.
#ICYMI: The USPTO recently held a webinar focusing on updates to director institution of trial proceedings in inter partes reviews and post-grant reviews at the #PTAB.
Reforms to increase transparency and consistency in PTAB decisions are crucial to promoting #innovation.
More about the webinar:
Recently, #C4IP Chief Policy Officer and Counsel Jamie Simpson spoke on a Federalist Society panel titled "SAP, Motorola, and the Future of #PTAB Reform," where she joined other legal experts to discuss recent Patent Trial and Appeal Board developments.
🎙️ Listen to the webinar here:
📜 The #PREVAIL Act would ensure that the #PTAB meets the America Invents Act's original goals: a #patent system that is efficient, predictable, and fair.
PREVAIL would also ensure an equal playing field for the many small and independent #inventors competing against large incumbents.
For more:
PTAB Issues Four IPR Written Decisions in Merck and Johns Hopkins Pembrolizumab Dispute
#PTAB #IPR #BigMoleculeWatch
www.bigmoleculewatch.com/2025/10/06/p...
#ICYMI: C4IP Chief Policy Officer and Counsel Jamie Simpson was quoted in a Bloomberg Law article commending ongoing changes to the #PTAB petition process, which will limit duplicative challenges and protect #innovators from potential abuses of the system by competitors.
For more 👇
🔍 Don't miss this op-ed by Russell Slifer:
"As former deputy director of the #USPTO, I've seen firsthand how the #PTAB's structure has created unforeseen opportunities for abuse. I know how vital it is to American prosperity to get #PTAB reform over the finish line in 2025."
For more:
PTAB Discretionarily Denies Two Petitions, Refers a Third to the Board in Amgen v. Bristol-Myers Squibb
#PTAB #BigMoleculeWatch
www.bigmoleculewatch.com/2025/08/18/p...
📽️ Check out our video on the recently reintroduced #PREVAIL Act.
This #bipartisan, landmark bill would reform the #PTAB to eliminate duplicative proceedings, providing more efficiency in the #patent system while also being fair to #patent owners and petitioners alike.
Watch the video here ⬇️
The #PREVAIL Act would ensure that the #PTAB meets the America Invents Act's original goals: a #patent system that is efficient, predictable, and fair.
PREVAIL would also ensure an equal playing field for the many small and independent #inventors competing against large incumbents.
Learn more:
An IDS is Now the Best Defense Against IPRs: Ecto World v. RAI patentlyo.com/patent/2025/... by @denniscrouch.bsky.social #priorart #PTAB #USPTO #patentlaw
Check out our latest IP Newsflash update titled, "Claim Construction Issues and Large Number of Claims Not Enough to Institute a Second Petition for Inter Partes Review" here: lnkd.in/gEskXKjm
By: Vincent Jones, Caitlin Olwell and Rubén H. Muñoz.
#IP #PatentLitigation #PTAB
📽️ Take a look at our new video all about the recently reintroduced #PREVAIL Act!
This #bipartisan, landmark #bill would reform the #PTAB to eliminate duplicative proceedings, providing more efficiency in the #patent system while also being fair to patent owners and petitioners alike.
Watch it ⬇️
#ICYMI: Last month, C4IP applauded the #USPTO's withdrawal of harmful #PTAB guidance.
"The USPTO's withdrawal of the 2022 PTAB guidance marks a critical course correction for American #innovation."
Read #C4IP Executive Director Frank Cullen's full statement ⬇️
This one tells the real story: #CRISPR #PatentWar is a high-profile legal dispute over ownership of #Cas9 gene-editing technology: #CVC ( #UCBerkeley #UniVienna #EmmanuelleCharpentier) vs. #BroadInstitute (aff. #Harvard + #MIT) - #USPTO and #PTAB ruled against CVC / granted patents #GMO #USgreed
The #USPTO has issued a new interim process for the institution of AIA proceedings that bifurcates consideration of inter partes review and post-grant review petitions into a discretionary denial phase, and a merits or non-discretionary phase.
Learn more: lnkd.in/graF-mvZ
#IP #PTAB
Check out our latest IP Newsflash update titled, "Federal Circuit: Private Sale by Inventor Does Not Trigger Prior Art Exception Under the AIA" here: lnkd.in/dJbqsh6X
By: Matt Lin, Jason Weil and Rachel Elsby
#FederalCircuit #IntellectualProperty #PTAB
📣 C4IP applauds the #USPTO's rescission of a 2022 memorandum that limited certain discretionary denials of institution at the #PTAB. By reversing this policy, the USPTO will reduce government waste, help prevent repetitive #patent challenges, and thus help American innovators protect their #IP.
🔗
